IGF1R and colorectal carcinoma: Through the CRC organoids and in vivo studies, they found that co-targeting IGF1R and YAP1 with picropodophyllin and verteporfin (IGF1R and YAP1 inhibitors, respectively) showed higher antitumor effects than picropodophyllin monotherapy.